NVCT · Nuvectis Pharma, Inc.

Nuvectis Pharma's Q1 2026 results reflect ongoing investment in its lead asset NXP900, with net loss widening to $6.1 million from $5.3 million year-over-year due to elevated operating expenses. R&D costs increased $0.4 million to $4.1 million, attributed to higher manufacturing ($0.4 million), employee compensation ($0.3 million), and clinical trial expenses ($0.2 million), offset partially by lower license fees. G&A rose $0.3 million to $2.2 million from increased professional services and compensation tied to public company operations. Cash burn reduced liquidity to $25.1 million from $31.6 million at year-end, signaling a need for potential future capital raises to support runway. CEO Ron Bentsur highlighted positive momentum in NXP900 Phase 1b enrollment at top US sites and synergistic preclinical data with sotorasib in NSCLC models presented at AACR, reinforcing the combination strategy. Investors should note the anticipated summer data readout as a key catalyst, amid disciplined operations focused on clinical milestones.